SATB1 and head and neck squamous cell carcinoma: In the context of standard-of-care for HNSCC patients with the majority receiving radiochemotherapy in the course of their disease, the actual contribution of SATB1 inhibition to radio- and/or chemosensitivity, or to avoiding secondary resistance during therapy, remains to be elucidated in greater detail in ex vivo and in vivo models.